Jean Thomas, MD
Neurology · Lewiston, IDNPI 1881695534
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,278 of the $3,731 with a category attached, or 61.0%. 22 manufacturers reported payments, led by Boston Scientific at 45.6% of the total. Reporting peaked in 2024 at $1,461 and has fallen 86.7% since, to $194 in 2025.
Across 77 payments — averaging $48.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- EMD Serono, Inc.$1K
- Neurocrine Biosciences, Inc.$185
- Lilly USA, LLC$156
- Argenx US, Inc.$81
- Biogen$72
- plus $515 from 16 others
What the payments were for
- Speaking & faculty fees$371%
- Travel & lodging$1,41738%
- Food & beverage$2,27861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $1,700 |
| EMD Serono, Inc. | 19 | $1,021 |
| Neurocrine Biosciences, Inc. | 7 | $185 |
| Lilly USA, LLC | 5 | $156 |
| Argenx US, Inc. | 3 | $81 |
| Biogen | 4 | $72 |
| TG Therapeutics, Inc. | 1 | $65 |
| Sanofi | 3 | $54 |
| Novartis | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 3 | $46 |
| Eisai Inc. | 2 | $42 |
| Acorda Therapeutics, Inc | 2 | $37 |
| AstraZeneca | 2 | $35 |
| GE HealthCare | 2 | $31 |
| Banner Life Sciences, LLC | 1 | $28 |
| Tanabe Pharma America, Inc. | 1 | $25 |
| AbbVie | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $14 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL DBS$840
- VERCISE$759
- Mavenclad$256
- INGREZZA$122
How this compares
$3,731 in reported general payments places this provider in the 70th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriflunomide | 68 | $180,126 |
| CopaxoneGlatiramer Acetate | 21 | $113,892 |
| VumerityDiroximel Fumarate | 12 | $101,043 |
| AustedoDeutetrabenazine | 11 | $82,937 |
| Dimethyl Fumarate | 17 | $41,412 |
| Aimovig AutoinjectorErenumab-Aooe | 51 | $36,407 |
| RytaryCarbidopa/Levodopa | 15 | $24,263 |
| GlatopaGlatiramer Acetate | 14 | $20,611 |
| Dalfampridine ErDalfampridine | 22 | $18,323 |
| Depakote SprinkleDivalproex Sodium | 23 | $16,526 |
| TopamaxTopiramate | 12 | $14,811 |
| VimpatLacosamide | 24 | $13,811 |
| Tegretol XrCarbamazepine | 30 | $12,645 |
| Diazepam | 26 | $11,190 |
| Pregabalin ErPregabalin | 12 | $9,941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $72 | $101,04312 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide | $19 | $34,222130 claims |
| PfizerDilantin | $11 | $4,01712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 59 neurology providers in Idaho.
Other neurology in Lewiston
- Mark KeaneLewiston$284
- Bradford TalcottIdaho Falls$252K
- Lawrence GreenNampa$193K
- Stephen VincentIdaho Falls$156K
- Nina BozinovCoeur D Alene$76K
- Angela PanaCoeur D Alene$37K
- Erich GarlandIdaho Falls$33K
- Sergei KashirnyBoise$20K
- Richard HammondTwin Falls$16K
- Kylie AbeMeridian$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.